The White House announced on March 20, 2026, the addition of three prescription drugs from Boehringer Ingelheim to its TrumpRx self-pay discount platform [1]. The newly listed medications include Jentadueto and Jentadueto XR for Type 2 diabetes, and Striverdi Respimat for chronic obstructive pulmonary disease (COPD), according to an administration statement [3]. Administration officials framed the move as a continuation of President Donald Trump’s push to lower prescription drug costs, a priority since his return to office in January 2025 [5]. The platform, launched in January 2026, is a central pillar of the administration’s strategy to provide direct price relief to consumers [4]. This marks the ninth pharmaceutical manufacturer to join the TrumpRx initiative, the White House said [6].
Reported Price Reductions and Competitive Analysis
Read Full Article: https://www.naturalnews.com/2026-03-24-white-house-expands-trumprx-diabetes-copd-medications.html
